UPDATE: J.P. Morgan Upgrades Bristol-Myers Squibb Ahead of Multiple Important Catalysts

In a report published Monday, J.P. Morgan analyst Chris Schott upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY ) from Neutral to Overweight, and raised the price target from $50.00 to $52.00. In the report, J.P. Morgan noted, “With Bristol shares having pulled back over the past several months,